Page 11«..10111213..2030..»

Category Archives: Global News Feed

Vantage Biosciences Doses First Patient in Phase 2 Clinical Study of Oral VX-01 for Non-Proliferative Diabetic Retinopathy

Posted: April 13, 2025 at 2:46 am

LONDON, April 11, 2025 (GLOBE NEWSWIRE) -- Vantage Biosciences, a clinical stage biotechnology company advancing innovative therapies for diabetic eye diseases, today announced that the first patient has been successfully dosed in its Phase 2 clinical study evaluating VX-01, an oral therapy for the treatment of non-proliferative diabetic retinopathy (NPDR).

See original here:
Vantage Biosciences Doses First Patient in Phase 2 Clinical Study of Oral VX-01 for Non-Proliferative Diabetic Retinopathy

Posted in Global News Feed | Comments Off on Vantage Biosciences Doses First Patient in Phase 2 Clinical Study of Oral VX-01 for Non-Proliferative Diabetic Retinopathy

BON Announces Apple Polyphenol Commercial Order Signed

Posted: April 13, 2025 at 2:46 am

XI'AN, China, April 11, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced a groundbreaking 24-month supply agreement worth $12M with Shanghai Yunsheng, China's premier functional ingredients distributor, to co-develop next-generation apple polyphenol-infused health solutions. The partnership leverages BON's patented extraction technology to deliver science-backed formulations combining antioxidant-rich apple polyphenols with plant-based proteins, proven to support weight management and metabolic health.

Follow this link:
BON Announces Apple Polyphenol Commercial Order Signed

Posted in Global News Feed | Comments Off on BON Announces Apple Polyphenol Commercial Order Signed

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

Posted: April 13, 2025 at 2:46 am

SAN DIEGO, April 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2025 financial results on Thursday, May 8, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.

Link:
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

Posted in Global News Feed | Comments Off on Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

ImPact Biotech Announces New Data Presentations at AUA 2025 Highlighting Safety and Efficacy of Padeliporfin VTP

Posted: April 13, 2025 at 2:46 am

- Company to present updated preliminary results from ENLIGHTED Phase 3 Study in LG UTUC -

Read the original post:
ImPact Biotech Announces New Data Presentations at AUA 2025 Highlighting Safety and Efficacy of Padeliporfin VTP

Posted in Global News Feed | Comments Off on ImPact Biotech Announces New Data Presentations at AUA 2025 Highlighting Safety and Efficacy of Padeliporfin VTP

Preliminary Results for the Year Ended 31 December 2024

Posted: April 13, 2025 at 2:46 am

April 11, 2025

Read the original:
Preliminary Results for the Year Ended 31 December 2024

Posted in Global News Feed | Comments Off on Preliminary Results for the Year Ended 31 December 2024

Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects

Posted: April 13, 2025 at 2:46 am

NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 11, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announces the filing of two groundbreaking patents for tapinarof (VTAMA®), including a dual active cocrystal, pairing the drug currently approved in the US for psoriasis and atopic dermatitis with a complementary drug substance known to address key patient needs in inflammatory skin conditions. The Company anticipates this combination drug approach could offer enhanced patient benefits over existing tapinarof formulations by addressing both therapeutic needs and known side effects, such as pain and itch, which are a known priority to sufferers of these conditions but typically overlooked by standard treatments that focus on the underlying disease alone.

See the original post:
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects

Posted in Global News Feed | Comments Off on Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects

Scilex Holding Company Announces 1-for-35 Reverse Stock Split

Posted: April 13, 2025 at 2:46 am

PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-35, to be effective as of 12:01 a.m. Eastern Time on April 15, 2025.

More:
Scilex Holding Company Announces 1-for-35 Reverse Stock Split

Posted in Global News Feed | Comments Off on Scilex Holding Company Announces 1-for-35 Reverse Stock Split

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

Posted: April 13, 2025 at 2:46 am

CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Markers of Cardiac Stress

See the article here:
BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

Posted in Global News Feed | Comments Off on BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements

Posted: April 13, 2025 at 2:46 am

- The universal oxygen carrier delivery capabilities of BXT-25 can be monitored, broadening its applications to treat hypoxic diseases

Read this article:
Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements

Posted in Global News Feed | Comments Off on Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements

Nika Pharmaceuticals, Inc. (NIKA) Latest Developments

Posted: April 13, 2025 at 2:46 am

HENDERSON, Nev., April 11, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA) published a report on the therapeutic effect and potential economic impact of ITV-1. The document contains the company’s findings on the effects of the drug on volunteers suffering from AIDS, cancer and other diseases. It details several examples of the curative effect of ITV-1 and its wider applicability beyond AIDS. You can read the document here or on our website.

Continued here:
Nika Pharmaceuticals, Inc. (NIKA) Latest Developments

Posted in Global News Feed | Comments Off on Nika Pharmaceuticals, Inc. (NIKA) Latest Developments

Page 11«..10111213..2030..»